|
|
(One intermediate revision not shown.) |
Line 3: |
Line 3: |
| <StructureSection load='4c1w' size='340' side='right'caption='[[4c1w]], [[Resolution|resolution]] 1.84Å' scene=''> | | <StructureSection load='4c1w' size='340' side='right'caption='[[4c1w]], [[Resolution|resolution]] 1.84Å' scene=''> |
| == Structural highlights == | | == Structural highlights == |
- | <table><tr><td colspan='2'>[[4c1w]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/"diplococcus_pneumoniae"_(klein_1884)_weichselbaum_1886 "diplococcus pneumoniae" (klein 1884) weichselbaum 1886]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4C1W OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4C1W FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[4c1w]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Streptococcus_pneumoniae Streptococcus pneumoniae]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4C1W OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4C1W FirstGlance]. <br> |
- | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=SLT:5-(ACETYLAMINO)-3,5-DIDEOXYNON-2-ULOPYRANONOSYL-(2- 3)-BETA-D-LYXO-HEXOPYRANOSYL-(1- 4)HEXOPYRANOSE'>SLT</scene>, <scene name='pdbligand=TRS:2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL'>TRS</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.84Å</td></tr> |
- | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4c1x|4c1x]]</td></tr>
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GAL:BETA-D-GALACTOSE'>GAL</scene>, <scene name='pdbligand=GLC:ALPHA-D-GLUCOSE'>GLC</scene>, <scene name='pdbligand=PRD_900025:3-sialyl-alpha-lactose'>PRD_900025</scene>, <scene name='pdbligand=SIA:O-SIALIC+ACID'>SIA</scene>, <scene name='pdbligand=TRS:2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL'>TRS</scene></td></tr> |
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4c1w FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4c1w OCA], [http://pdbe.org/4c1w PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4c1w RCSB], [http://www.ebi.ac.uk/pdbsum/4c1w PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4c1w ProSAT]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4c1w FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4c1w OCA], [https://pdbe.org/4c1w PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4c1w RCSB], [https://www.ebi.ac.uk/pdbsum/4c1w PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4c1w ProSAT]</span></td></tr> |
| </table> | | </table> |
| + | == Function == |
| + | [https://www.uniprot.org/uniprot/Q4LB86_STREE Q4LB86_STREE] |
| <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
Line 19: |
Line 21: |
| | | |
| ==See Also== | | ==See Also== |
- | *[[Carbohydrate binding domain from Streptococcus pneumoniae NanA sialidase complexed with 3'-sialyllactose|Carbohydrate binding domain from Streptococcus pneumoniae NanA sialidase complexed with 3'-sialyllactose]] | + | *[[Neuraminidase 3D structures|Neuraminidase 3D structures]] |
- | *[[Sialidase|Sialidase]]
| + | |
| == References == | | == References == |
| <references/> | | <references/> |
Line 26: |
Line 27: |
| </StructureSection> | | </StructureSection> |
| [[Category: Large Structures]] | | [[Category: Large Structures]] |
- | [[Category: Connaris, H]] | + | [[Category: Streptococcus pneumoniae]] |
- | [[Category: Potter, J A]] | + | [[Category: Connaris H]] |
- | [[Category: Taylor, G L]] | + | [[Category: Potter JA]] |
- | [[Category: Yang, L]] | + | [[Category: Taylor GL]] |
- | [[Category: Carbohydrate-binding module]] | + | [[Category: Yang L]] |
- | [[Category: Sialic acid binding]]
| + | |
- | [[Category: Sugar binding protein]]
| + | |
| Structural highlights
4c1w is a 1 chain structure with sequence from Streptococcus pneumoniae. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
| Method: | X-ray diffraction, Resolution 1.84Å |
Ligands: | , , , , |
Resources: | FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT |
Function
Q4LB86_STREE
Publication Abstract from PubMed
There is a need for new approaches for the control of influenza given the burden caused by annual seasonal outbreaks, the emergence of viruses with pandemic potential, and the development of resistance to current antiviral drugs. We show that multivalent biologics, engineered using carbohydrate-binding modules specific for sialic acid, mask the cell-surface receptor recognized by the influenza virus and protect mice from a lethal challenge with 2009 pandemic H1N1 influenza virus. The most promising biologic protects mice when given as a single 1-mug intranasal dose 7 d in advance of viral challenge. There also is sufficient virus replication to establish an immune response, potentially protecting the animal from future exposure to the virus. Furthermore, the biologics appear to stimulate inflammatory mediators, and this stimulation may contribute to their protective ability. Our results suggest that this host-targeted approach could provide a front-line prophylactic that has the potential to protect against any current and future influenza virus and possibly against other respiratory pathogens that use sialic acid as a receptor.
Prevention of influenza by targeting host receptors using engineered proteins.,Connaris H, Govorkova EA, Ligertwood Y, Dutia BM, Yang L, Tauber S, Taylor MA, Alias N, Hagan R, Nash AA, Webster RG, Taylor GL Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):6401-6. doi:, 10.1073/pnas.1404205111. Epub 2014 Apr 14. PMID:24733924[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Connaris H, Govorkova EA, Ligertwood Y, Dutia BM, Yang L, Tauber S, Taylor MA, Alias N, Hagan R, Nash AA, Webster RG, Taylor GL. Prevention of influenza by targeting host receptors using engineered proteins. Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):6401-6. doi:, 10.1073/pnas.1404205111. Epub 2014 Apr 14. PMID:24733924 doi:http://dx.doi.org/10.1073/pnas.1404205111
|